CytoDyn names Robert E. Hoffman CEO, succeeding Jacob Lalezari

CYDY•2026-10-19

CytoDyn appointed principal accounting officer Robert E. Hoffman CEO, effective Oct. 20, 2026, replacing Jacob Lalezari. Lalezari will become head of research and translational sciences, focusing on solid-tumor oncology opportunities for leronlimab.

1. Leadership change

CytoDyn appointed principal accounting officer Robert E. Hoffman CEO, effective Oct. 20, 2026, replacing Jacob Lalezari, who has been CEO since November 2023. Lalezari will become head of research and translational sciences, focusing on new solid-tumor oncology opportunities for leronlimab.

CytoDyn names Robert E. Hoffman CEO, succeeding Jacob Lalezari

1. Leadership change

Related News

Saba Capital Management reports acquisition of $1,976 in Gabelli Healthcare & WellnessRx Trust common shares

Oil stocks in US strategic petroleum reserve fall to lowest level since 1982

ConnectM issues $1.39 million secured convertible note to Ascent Partners Fund

US reportedly set to announce certification of Boeing 737 MAX 10 Tuesday

ASML announces dividend of R$ 0.15901887100 per unit